ERS Publications Podcasts

As part of the March issue, the European Respiratory Journal presents the latest in its series of podcasts. To mark World TB Day, chief editor Martin Kolb interviews section editor Giovanni Battista Migliori about the following articles.

Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017; 49: 1700387.

Cabibbe AM, Sotgiu G, Izco S, et al. Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens. Eur Respir J 2017; 50: 1702292.

Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.

Guglielmetti L, Jaspard M, Le Dû D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1601799.

Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J 2017; 50: 1701354.

Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J 2017; 50: 1701462.

Van der Werf MJ, Hollo V, Ködmön C, et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J 2017; 49: 1601992.

As part of the March issue, the European Respiratory Journal presents the latest in its series of podcasts. To mark World TB Day, chief editor Martin Kolb interviews section editor Giovanni Battista Migliori about the following articles.

----

Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017; 49: 1700387.

Cabibbe AM, Sotgiu G, Izco S, et al. Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens. Eur Respir J 2017; 50: 1702292.

Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.

Guglielmetti L, Jaspard M, Le Dû D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1601799.

Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J 2017; 50: 1701354.

Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J 2017; 50: 1701462.

Van der Werf MJ, Hollo V, Ködmön C, et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J 2017; 49: 1601992.

As part of the February issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Martin Kolb interviews the Jørgen Vestbo (The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK) about the important difference between standard efficacy trials and real-world effectiveness trials such as the Salford Lung Study.

As part of the February issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Martin Kolb interviews Jørgen Vestbo (The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK) about the important difference between standard efficacy trials and real-world effectiveness trials such as the Salford Lung Study.

As part of the January issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy chief editor James Chalmers interviews the Anthony De Soyza (Newcastle University, Newcastle, UK) and Timothy Aksamit (Mayo Clinic, Rochester, MN, USA) about the RESPIRE1 and RESPIRE2 trials of ciprofloxacin in non-cystic fibrosis bronchiectasis. These two global phase III trials enrolled a total of 937 and test two dosing regimens tested (identical dose). The range of treatment estimates favours use of a ciprofloxacin dry powder inhaler (DPI), which was overall, well tolerated, with high compliance and an excellent safety profile. The ciprofloxacin DPI 14-day regimen gave a 144-day delay in the to time to first exacerbation and a 25% reduction in the frequency of exacerbations, and the 28-day regimen gave a 138-day delay in to time to first exacerbation and a 28% reduction in frequency of exacerbations.

As part of the December issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Marc Humbert interviews the incoming Chief Editor Martin Kolb and Deputy Chief Editor James Chalmers about the future of the ERJ, and reflects on his own time as Chief Editor.

As part of the November issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Marc Humbert discusses the ERS statement on the diagnosis and treatment of pulmonary disease caused by α1-antitrypsin deficiency with Task Force chairs Marc Miravitlles (Hospital Universitari Vall d'Hebron, Barcelona, Spain) and Robert A. Stockley (Queen Elizabeth Hospital, Birmingham, UK).

As part of the November issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Marc Humbert discusses the ERS statement on the diagnosis and treatment of pulmonary disease caused by α1-antitrypsin deficiency with Task Force chairs Marc Miravitlles (Hospital Universitari Vall d'Hebron, Barcelona, Spain) and Robert A. Stockley (Queen Elizabeth Hospital, Birmingham, UK).

As part of the December issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Marc Humbert interviews the incoming Chief Editor Martin Kolb and Deputy Chief Editor James Chalmers about the future of the ERJ, and reflects on his own time as Chief Editor.

As part of the November issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Marc Humbert discusses the ERS statement on the diagnosis and treatment of pulmonary disease caused by α1-antitrypsin deficiency with Task Force chairs Marc Miravitlles (Hospital Universitari Vall d'Hebron, Barcelona, Spain) and Robert A. Stockley (Queen Elizabeth Hospital, Birmingham, UK).